
OKUR Stock Forecast & Price Target
OKUR Analyst Ratings
Bulls say
OnKure Therapeutics Inc demonstrated a narrower-than-expected net loss of $1.14 per share for 2Q25, indicating more efficient financial management than initially anticipated. Additionally, the clinical trial of OKI-219 showed promising results, as it was well-tolerated across all dose levels with minimal adverse events reported. This favorable safety profile may enhance the potential market acceptance of OKI-219, positioning OnKure favorably within the competitive landscape of cancer therapeutics.
Bears say
OnKure Therapeutics is projected to incur a substantial full-year net loss of $4.56 per share in 2025, reflecting a minor improvement from a previous estimate of $4.75 per share. The company faces several risks that may negatively impact its financial performance, including potential negative clinical outcomes with its lead asset, OKI-219, and delays in advancing its pipeline candidates. Furthermore, challenges in obtaining timely regulatory approvals and increasing competition in the biopharmaceutical space contribute to a pessimistic outlook for the company's future profitability and stock performance.
This aggregate rating is based on analysts' research of OnKure Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
OKUR Analyst Forecast & Price Prediction
Start investing in OKUR
Order type
Buy in
Order amount
Est. shares
0 shares